Tricuspid Regurgitation Related to Cardiac Implantable Electronic Devices: An Integrative Review

Gelves-Meza, Julian; Lang, Roberto M.; Valderrama-Achury, María Daniela; Zamorano, José Luís; Vargas-Acevedo, Catalina; Medina, Hector Manuel; Salazar, Gabriel

doi:10.1016/j.echo.2022.08.004

Cited by 32 publications

(25 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pathophysiological reasons underpinning the higher burden of TR in patients with CRM leads include lead‐related tricuspid valve damage (leaflet impingement, lead adherence, perforation, entanglement in subvalvular apparatus, fibrosis etc. ) 6 and concurrent progression of the underlying cardiac disease. TR begets TR through annular dilatation, right ventricular dysfunction or pulmonary hypertension related to left heart disease 6 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Alternatives to transvenous lead placement in a patient undergoing surgical tricuspid valve repair

Zhu

Rubinstein

Leet

et al. 2023

Pacing Clinical Electrophis

View full text Add to dashboard Cite

Tricuspid regurgitation is a widely recognised phenomenon in patients with transvenous cardiac rhythm management (CRM) devices. If tricuspid valve repair or replacement is to be considered, what to do with the existing CRM system requires scrutiny with multidisciplinary input. We present a case of multifactorial tricuspid regurgitation in a 48‐year‐old female with giant cell myocarditis and a transvenous implantable cardioverter‐defibrillator (ICD). Key considerations in management and alternative CRM options are discussed.

show abstract

Section: Discussionmentioning

confidence: 99%

“…) 6 and concurrent progression of the underlying cardiac disease. TR begets TR through annular dilatation, right ventricular dysfunction or pulmonary hypertension related to left heart disease 6 . In particular, ICD leads, which have a larger caliber and greater stiffness, are more likely to result in TR 7 …”

Section: Discussionmentioning

confidence: 99%

Alternatives to transvenous lead placement in a patient undergoing surgical tricuspid valve repair

Zhu

Rubinstein

Leet

et al. 2023

Pacing Clinical Electrophis

View full text Add to dashboard Cite

show abstract

“…2 Contemporary leads are, perhaps, thicker than ideal considering theoretical problems of venous occlusion and tricuspid valve disruption. [3][4][5][6] However, attempts at reducing lead thickness have led to the recall of two leads highlighting risks involved with changes in lead design. Risks may not be easy to spot and may only be identified in retrospect.…”

Section: N V I T E D E D I T O R I a Lmentioning

confidence: 99%

“…Lead diameter may not be the critical factor for these lead-related complications, however. [3][4][5][6] More commonly, venous thrombosis is related to the number of leads traversing the venous system and tricuspid valve issues are related to the number of leads crossing the tricuspid valve, frequency of manipulation, and the number of procedures. If the investigational lead fails, an additional lead may be required potentially exposing patients to increased rates of complications.…”

Section: N V I T E D E D I T O R I a Lmentioning

confidence: 99%

“…A thinner lead may reduce tricuspid regurgitation and prevent venous occlusion, but these are not being evaluated explicitly. Lead diameter may not be the critical factor for these lead‐related complications, however 3–6 . More commonly, venous thrombosis is related to the number of leads traversing the venous system and tricuspid valve issues are related to the number of leads crossing the tricuspid valve, frequency of manipulation, and the number of procedures.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The LEADR ICD lead study: Is thinner better?

Anderson

Olshansky

2022

Cardiovasc electrophysiol

View full text Add to dashboard Cite

Transcatheter tricuspid valve intervention in the presence of a cardiac implantable electronic device; state of the art review

Basman,

Jamal,

Yoon

et al. 2024

Cathet Cardio Intervent

View full text Add to dashboard Cite

A large proportion of patients referred for transcatheter tricuspid valve intervention (TTVI) will have the presence of a cardiac implantable electronic device (CIED). In such patients, surgical correction of tricuspid regurgitation (TR) is associated with high rates of morbidity and mortality. Transvenous lead extraction (TLE) could potentially ameliorate CIED‐induced TR; however, it carries inherent risks and frequently does not result in TR improvement. As multiple TTVI devices are in trial to gain regulatory approval, understanding which therapy is most appropriate among patients with a CIED is essential. This review centers on the nonsurgical treatment, including TLE and transcatheter tricuspid valve repair and replacement options, aimed at enhancing outcomes in patients with TR who also have concurrent CIEDs.

show abstract

Tricuspid Regurgitation Related to Cardiac Implantable Electronic Devices: An Integrative Review

Cited by 32 publications

References 79 publications

Alternatives to transvenous lead placement in a patient undergoing surgical tricuspid valve repair

Alternatives to transvenous lead placement in a patient undergoing surgical tricuspid valve repair

The LEADR ICD lead study: Is thinner better?

Transcatheter tricuspid valve intervention in the presence of a cardiac implantable electronic device; state of the art review

Contact Info

Product

Resources

About